scispace - formally typeset
Search or ask a question
Institution

Jagiellonian University

EducationKrakow, Poland
About: Jagiellonian University is a education organization based out in Krakow, Poland. It is known for research contribution in the topics: Population & Catalysis. The organization has 17438 authors who have published 44092 publications receiving 862633 citations. The organization is also known as: Academia Cracoviensis & Akademia Krakowska.


Papers
More filters
Journal ArticleDOI
TL;DR: Ielalisib plus BR is superior to BR alone, improving PFS and OS, and represents an important new treatment option for patients with R/R CLL.
Abstract: Summary Background Bendamustine plus rituximab is a standard of care for the management of patients with relapsed or refractory chronic lymphocytic leukaemia. New therapies are needed to improve clinically relevant outcomes in these patients. We assessed the efficacy and safety of adding idelalisib, a first-in-class targeted phosphoinositide-3-kinase δ inhibitor, to bendamustine plus rituximab in this population. Methods For this international, multicentre, double-blind, placebo-controlled trial, adult patients (≥18 years) with relapsed or refractory chronic lymphocytic leukaemia requiring treatment who had measurable lymphadenopathy by CT or MRI and disease progression within 36 months since their last previous therapy were enrolled. Patients were randomly assigned (1:1) by a central interactive web response system to receive bendamustine plus rituximab for a maximum of six cycles (bendamustine: 70 mg/m 2 intravenously on days 1 and 2 for six 28-day cycles; rituximab: 375 mg/m 2 on day 1 of cycle 1, and 500 mg/m 2 on day 1 of cycles 2–6) in addition to either twice-daily oral idelalisib (150 mg) or placebo until disease progression or intolerable study drug-related toxicity. Randomisation was stratified by high-risk features ( IGHV , del[17p], or TP53 mutation) and refractory versus relapsed disease. The primary endpoint was progression-free survival assessed by an independent review committee in the intention-to-treat population. This trial is ongoing and is registered with ClinicalTrials.gov, number NCT01569295. Findings Between June 26, 2012, and Aug 21, 2014, 416 patients were enrolled and randomly assigned to the idelalisib (n=207) and placebo (n=209) groups. At a median follow-up of 14 months (IQR 7–18), median progression-free survival was 20·8 months (95% CI 16·6–26·4) in the idelalisib group and 11·1 months (8·9–11·1) in the placebo group (hazard ratio [HR] 0·33, 95% CI 0·25–0·44; p vs 52 [25%] of 209). Serious adverse events, including febrile neutropenia, pneumonia, and pyrexia, were more common in the idelalisib group (140 [68%] of 207 patients) than in the placebo group (92 [44%] of 209). Treatment-emergent adverse events leading to death occurred in 23 (11%) patients in the idelalisib group and 15 (7%) in the placebo group, including six deaths from infections in the idelalisib group and three from infections in the placebo group. Interpretation Idelalisib in combination with bendamustine plus rituximab improved progression-free survival compared with bendamustine plus rituximab alone in patients with relapsed or refractory chronic lymphocytic leukaemia. However, careful attention needs to be paid to management of serious adverse events and infections associated with this regimen during treatment selection. Funding Gilead Sciences Inc.

191 citations

Journal ArticleDOI
TL;DR: In this paper, an upper bound of 90% C.L. on the ratio between the U coupling constant and the fine structure constant of alpha/alpha < 1.7 fb(-1) was established.

190 citations

Journal ArticleDOI
TL;DR: U samic nornicy rudej Clethrionomys glareolus określano zuzycie pokarmu i energie strawioną (asymilacje) w ciŅgu calego okresu ciązy i laktacji (18 + 18 dni).
Abstract: U samic nornicy rudej Clethrionomys glareolus (Schreber, 1780) określano zuzycie pokarmu i energie strawioną (asymilacje) w ciągu calego okresu ciązy i laktacji (18 + 18 dni).

190 citations

Journal ArticleDOI
TL;DR: The results indicate that the clinically used photosensitizer VP is a potent inhibitor of cell growth in retinoblastoma cells, disrupting YAP-TEAD signaling and pluripotential marker OCT4.

189 citations

Journal ArticleDOI
TL;DR: In this paper, the changes in the structure of wool fiber keratin were studied by means of Fourier-transform Infrared and Raman Spectroscopy, and the attempt of interruption of this process in the presence of siliceous compounds was made.

189 citations


Authors

Showing all 17729 results

NameH-indexPapersCitations
Roxana Mehran141137899398
Brad Abbott137156698604
M. Morii1341664102074
M. Franklin134158195304
John Huth131108785341
Wladyslaw Dabrowski12999079728
Rostislav Konoplich12881173790
Michel Vetterli12890176064
Francois Corriveau128102275729
Christoph Falk Anders12673468828
Tomasz Bulik12169886211
Elzbieta Richter-Was11879369127
S. H. Robertson116131158582
S. J. Chen116155962804
David M. Stern10727147461
Network Information
Related Institutions (5)
University of Tübingen
84.1K papers, 3M citations

90% related

University of Milan
139.7K papers, 4.6M citations

90% related

University of Turin
77.9K papers, 2.4M citations

89% related

University of Padua
114.8K papers, 3.6M citations

89% related

University of Vienna
95.8K papers, 2.9M citations

89% related

Performance
Metrics
No. of papers from the Institution in previous years
YearPapers
2023162
2022510
20212,769
20202,776
20192,736
20182,735